enzh-TWfrdeitjaptrues

Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

Young WM International Support Group Meeting Monday, May 16th at 7:15PM U.S. ET

Young WM International Support Group Meeting Monday, May 16th at 7:15PM U.S. ET

WM patients and caregivers under the age of 50:Join the Young WM International Support Group on May 16th with special guest, Dr. Shayna Sarosiek!

Read more..

Waldenstrom’s Macroglobulinemia (WM): Treatment Progress Workshop

Waldenstrom’s Macroglobulinemia (WM): Treatment Progress Workshop

Workshop Date and Time: Wednesday, May 25, 2022, 1:30 – 2:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast. Click below to learn more or register for this workshop.

Read more..

IWMF Torch April, 2022 - Bing Neel Syndrome, Dr. Jorge Castillo

IWMF Torch April, 2022 - Bing Neel Syndrome, Dr. Jorge Castillo

In this issue of the IWMF Torch, Dr. Jorge Castillo reviews the disgnosis, indications to treat, and treatment options for Bing Neel Syndrome (BNS) in patients with WM, as these have a direct impact on further understanding the choices available to manage BNS.

Read more..

Covid Antibodies, CAR-T & More. Can We Feel Hopeful this Spring?

Covid Antibodies, CAR-T & More. Can We Feel Hopeful this Spring?

Our IWMF Support Group Leaders and International Affiliates had the pleasure of meeting with Dr. Shayna Sarosiek of Dana-Farber Cancer Institute this week. Dr. Sarosiek covered many topics, including Evusheld, CAR-T therapy, and WM treatments on the horizon. This is a fabulous and timely presentation you don't want to miss!

Read more..

Waldenström Macroglobulinemia Treatment Decisions: What’s Right for You?

Waldenström Macroglobulinemia Treatment Decisions: What’s Right for You?

When faced with a WM diagnosis, what determines the best treatment for YOU? In this 30-minute webinar, Dr. Jorge Castillo will review key factors that affect treatment decisions, emerging treatment research, and tips for partnering with your healthcare team.

Read more..

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Treatment Regimens

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Treatment Regimens

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.

Read more..

Living Well with Waldenstrom's Macroglobulinemia (FREE WEBINAR)

Living Well with Waldenstrom's Macroglobulinemia (FREE WEBINAR)

This program is designed to provide attendees with essential information that  will help you participate more actively and confidently in decisions about your  Waldenström Macroglobulinemia treatment and survivorship.

Read more..

Targeted Drug Found Effective as Initial Treatment for Waldenström Macroglobulinemia

Targeted Drug Found Effective as Initial Treatment for Waldenström Macroglobulinemia

When a clinical trial showed the targeted drug ibrutinib to be highly effective in patients with a form of lymphoma called Waldenström macroglobulinemia, the results were so compelling that the U.S. Food and Drug Administration approved the drug for all patients with the disease, even though the trial included only patients previously treated with other agents.

Read more..

IGM-Related Amyloidosis - by Dr. Shayna Sarosiek (The Torch, Jan 2022)

IGM-Related Amyloidosis - by Dr. Shayna Sarosiek (The Torch, Jan 2022)

The cover article for the first issue of The Torch for the new year is by Dr. Shayna Sarosiek, of the Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute. She discusses amyloidosis, its diagnosis, symptoms, and treatments. While it’s a relatively rare complication of a rare disease, it is prudent for us to be aware of it.

Read more..

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

Steven P. Treon, MD, MA, PhD, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with Waldenström macroglobulinemia with MYDD88 and CXCR4 mutations. These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

Read more..